QQQ   270.14 (-0.09%)
TSLA   1,491.84 (+0.33%)
BA   167.22 (+1.30%)
QQQ   270.14 (-0.09%)
TSLA   1,491.84 (+0.33%)
BA   167.22 (+1.30%)
QQQ   270.14 (-0.09%)
TSLA   1,491.84 (+0.33%)
BA   167.22 (+1.30%)
QQQ   270.14 (-0.09%)
TSLA   1,491.84 (+0.33%)
BA   167.22 (+1.30%)
Log in

NASDAQ:SGENSeattle Genetics Stock Price, Forecast & News

$165.07
-3.97 (-2.35 %)
(As of 08/5/2020 09:38 AM ET)
Add
Compare
Today's Range
$162.84
Now: $165.07
$168.73
50-Day Range
$155.56
MA: $170.60
$184.43
52-Week Range
$65.44
Now: $165.07
$187.99
Volume702,402 shs
Average Volume1.10 million shs
Market Capitalization$28.72 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.41
Seattle Genetics, Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas. It also conducts various clinical trials to evaluate the combination of ADCETRIS and nivolumab to treat patients with relapsed or refractory, or transplant-ineligible, advanced classical Hodgkin lymphoma; relapsed or refractory B-cell and T-cell non-Hodgkin lymphomas; second-line Hodgkin lymphoma; and relapsed/refractory classical Hodgkin lymphoma, as well as to treat Hodgkin lymphoma in patients with age 60 years or older. In addition, the company develops Enfortumab vedotin, ADC composed of an anti-Nectin-4 monoclonal antibody to treat bladder cancer, and ovarian and lung cancers; Tucatinib, an oral tyrosine kinase inhibitor for HER2-positive metastatic breast cancer; and Tisotumab Vedotin, an ADC composed of a human antibody that binds to tissue factor to treat various solid tumors, including cervical, ovarian, prostate, and bladder. Further, it develops early-stage clinical product candidates comprising ladiratuzumab vedotin, an ADC targeting LIV-1 and metastatic triple-negative breast cancer; SGN-CD48A; SEA-BCMA for patients with relapsed or refractory multiple myeloma; and SGN-2FF for patients with advanced solid tumors. It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Progenics Pharmaceuticals Inc.; Unum Therapeutics, Inc.; Pieris Pharmaceuticals, Inc.; Pieris Pharmaceuticals AG; Takeda Pharmaceutical Company Limited; Astellas Pharma, Inc.; and Agensys, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.
Read More
Seattle Genetics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.28 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:SGEN
CUSIP81257810
Phone425-527-4000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$916.71 million
Book Value$10.43 per share

Profitability

Net Income$-158,650,000.00

Miscellaneous

Employees1,605
Market Cap$28.72 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$165.07
-3.97 (-2.35 %)
(As of 08/5/2020 09:38 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for SGEN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Seattle Genetics (NASDAQ:SGEN) Frequently Asked Questions

How has Seattle Genetics' stock been impacted by COVID-19 (Coronavirus)?

Seattle Genetics' stock was trading at $104.51 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SGEN stock has increased by 57.9% and is now trading at $165.07.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Seattle Genetics?

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seattle Genetics in the last year. There are currently 1 sell rating, 8 hold ratings, 11 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Seattle Genetics
.

When is Seattle Genetics' next earnings date?

Seattle Genetics is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Seattle Genetics
.

How were Seattle Genetics' earnings last quarter?

Seattle Genetics, Inc. (NASDAQ:SGEN) announced its quarterly earnings results on Thursday, July, 30th. The biotechnology company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($0.58) by $0.46. The biotechnology company had revenue of $278 million for the quarter, compared to the consensus estimate of $256.74 million. Seattle Genetics had a negative return on equity of 18.32% and a negative net margin of 25.17%.
View Seattle Genetics' earnings history
.

What guidance has Seattle Genetics issued on next quarter's earnings?

Seattle Genetics updated its FY 2020 After-Hours earnings guidance on Thursday, July, 30th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.025-1.1 billion, compared to the consensus revenue estimate of $1.08 billion.

What price target have analysts set for SGEN?

21 equities research analysts have issued twelve-month price objectives for Seattle Genetics' shares. Their forecasts range from $95.00 to $200.00. On average, they expect Seattle Genetics' stock price to reach $151.17 in the next year. This suggests that the stock has a possible downside of 8.4%.
View analysts' price targets for Seattle Genetics
.

Has Seattle Genetics been receiving favorable news coverage?

News headlines about SGEN stock have been trending somewhat negative recently, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Seattle Genetics earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the immediate future.
View the latest news about Seattle Genetics
.

Who are some of Seattle Genetics' key competitors?

What other stocks do shareholders of Seattle Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seattle Genetics investors own include NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), AbbVie (ABBV), Immunomedics (IMMU), Starbucks (SBUX), Micron Technology (MU), Johnson & Johnson (JNJ), Netflix (NFLX) and salesforce.com (CRM).

Who are Seattle Genetics' key executives?

Seattle Genetics' management team includes the following people:
  • Dr. Clay B. Siegall, Co-Founder, Chairman, Pres & CEO (Age 58)
  • Mr. Todd E. Simpson, Chief Financial Officer (Age 58)
  • Dr. Vaughn B. Himes, Chief Technology Officer (Age 58)
  • Dr. Roger D. Dansey M.D., Chief Medical Officer (Age 62)
  • Ms. Jean I. Liu, Gen. Counsel, Exec. VP of Legal Affairs & Corp. Sec. (Age 51)

What is Seattle Genetics' stock symbol?

Seattle Genetics trades on the NASDAQ under the ticker symbol "SGEN."

Who are Seattle Genetics' major shareholders?

Seattle Genetics' stock is owned by a variety of retail and institutional investors. Top institutional investors include First Trust Advisors LP (0.50%), Sumitomo Mitsui Trust Holdings Inc. (0.37%), Frontier Capital Management Co. LLC (0.35%), Candriam Luxembourg S.C.A. (0.23%), ProShare Advisors LLC (0.07%) and Manning & Napier Group LLC (0.07%). Company insiders that own Seattle Genetics stock include Bros Advisors Lp Baker, Charles R Romp, Clay B Siegall, Daniel G Welch, Darren S Cline, David W Gryska, Jean I Liu, Lip Bu Tan, Marc E Lippman, Roger D Dansey, Srinivas Akkaraju, Todd E Simpson and Vaughn B Himes.
View institutional ownership trends for Seattle Genetics
.

Which major investors are selling Seattle Genetics stock?

SGEN stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, First Trust Advisors LP, Oregon Public Employees Retirement Fund, Rhenman & Partners Asset Management AB, DekaBank Deutsche Girozentrale, Zurcher Kantonalbank Zurich Cantonalbank, IFM Investors Pty Ltd, and Cordatus Wealth Management LLC. Company insiders that have sold Seattle Genetics company stock in the last year include Bros Advisors Lp Baker, Charles R Romp, Clay B Siegall, Daniel G Welch, David W Gryska, Jean I Liu, Lip Bu Tan, Marc E Lippman, Roger D Dansey, Srinivas Akkaraju, Todd E Simpson, and Vaughn B Himes.
View insider buying and selling activity for Seattle Genetics
.

Which major investors are buying Seattle Genetics stock?

SGEN stock was bought by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Robeco Institutional Asset Management B.V., MERIAN GLOBAL INVESTORS UK Ltd, State of Alaska Department of Revenue, Columbus Circle Investors, Assenagon Asset Management S.A., UBS Group AG, and Prudential PLC.
View insider buying and selling activity for Seattle Genetics
.

How do I buy shares of Seattle Genetics?

Shares of SGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Seattle Genetics' stock price today?

One share of SGEN stock can currently be purchased for approximately $165.07.

How big of a company is Seattle Genetics?

Seattle Genetics has a market capitalization of $28.72 billion and generates $916.71 million in revenue each year. The biotechnology company earns $-158,650,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis. Seattle Genetics employs 1,605 workers across the globe.

What is Seattle Genetics' official website?

The official website for Seattle Genetics is www.seattlegenetics.com.

How can I contact Seattle Genetics?

Seattle Genetics' mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The biotechnology company can be reached via phone at 425-527-4000 or via email at [email protected]

This page was last updated on 8/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.